Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13787
Abstract: Plasma cell‐free DNA (cfDNA) analysis to track estrogen receptor 1 (ESR1) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breast cancer (MBC).… read more here.
Keywords: cell; circulating tumor; ctc derived; esr1 mutations ... See more keywords
Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing
Sign Up to like & getrecommendations! Published in 2017 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-017-4487-y
Abstract: PurposeWe aimed to develop a highly sensitive method to detect ESR1 mutations in cell-free DNA (cfDNA) using next-generation sequencing with molecular barcode (MB–NGS) targeting the hotspot segment (c.1600–1713).MethodsThe sensitivity of MB–NGS was tested using serially… read more here.
Keywords: breast; barcode; patients metastatic; breast cancer ... See more keywords
Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing
Sign Up to like & getrecommendations! Published in 2018 at "Modern Pathology"
DOI: 10.1038/s41379-018-0116-5
Abstract: Estrogen receptor-α (ER-α), encoded by ESR1, is detected by immunohistochemistry in approximately 70% of invasive breast cancers and serves as a strong predictive biomarker. ESR1-activating mutations in the ligand-binding domain have been reported in up… read more here.
Keywords: immunohistochemistry; breast; breast cancer; cancer ... See more keywords
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
Sign Up to like & getrecommendations! Published in 2017 at "Nature Communications"
DOI: 10.1038/s41467-017-01864-y
Abstract: Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, endocrine-resistant setting. No naturally occurring… read more here.
Keywords: breast cancer; resistance; naturally occurring; endocrine resistance ... See more keywords
ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Cancer research"
DOI: 10.1158/0008-5472.can-25-1339
Abstract: Endocrine therapy (ET) is the standard of care for estrogen receptor-positive (ER+) breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer… read more here.
Keywords: cancer; breast cancer; estrogen receptor; ferroptosis ... See more keywords
Abstract 2220: Dynamic development of ESR1 mutations in circulating tumor DNA (ctDNA) is associated with prognosis of patients with metastatic breast cancer (MBC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2220
Abstract: Background: Relapse and endocrine resistance are major clinical challenges in the management of patients with MBC because it is a dynamic phenomenon including development of ESR1 mutations. The monitoring of ctDNA and circulating tumor cells… read more here.
Keywords: time; patients esr1; prognosis; time point ... See more keywords
Abstract 6701: 6-color Crystal Digital PCR for the high-plex detection of 10 ESR1 mutations in breast cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6701
Abstract: Introduction. ESR1 mutations have emerged as a key mechanism of resistance to endocrine therapy in estrogen-receptor-positive (ER+) breast cancer, thus detection of ESR1 mutations is crucial to monitor during patient treatment. We evaluated a novel… read more here.
Keywords: color; esr1 mutations; breast cancer; crystal digital ... See more keywords
Abstract 4570: ESR1-mutant circulating tumor DNA is associated with plasma interleukin-2 (IL-2) leading to circulating tumor cell proliferation in metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-4570
Abstract: Immune suppression is one of the most important causes of metastasis in metastatic breast cancer (MBC). Monitoring circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in patients with MBC is predictive of a worse… read more here.
Keywords: cancer; metastatic breast; tumor; circulating tumor ... See more keywords
Abstract P4-04-09: New oral SERD elacestrant (RAD1901) shows efficacy in breast cancer models harbouring ESR1 mutations and enhances the antiproliferative activity of mTORC1 and CDK4/6 inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-p4-04-09
Abstract: Background: Targeting estrogen receptor (ER) signalling is the main therapeutic option for ER+ breast cancer (BC). However, over 30% of patients relapse with endocrine resistance emphasising the need for improved therapeutic strategies. The prevalence of… read more here.
Keywords: elacestrant; cdk4; breast cancer; cancer ... See more keywords
Abstract PD8-08: ESR1 mutations confer novel metastatic functions in genome-edited breast cancer cell models
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-pd8-08
Abstract: Background: Estrogen receptor alpha (ERα), encoded by the ESR1 gene, is expressed in approximately 70% of breast cancers. Recent studies conducted by us and others have shown that somatic mutations in ESR1 gene play a… read more here.
Keywords: cell models; breast cancer; cancer; cell ... See more keywords
Abstract P2-07-16: Rising ESR1 Mutations in Circulating Tumor DNA (ctDNA) Mediate Endocrine Therapy (ET) Resistance to Everolimus and ET but Retain Sensitivity to Fulvestrant in HR+/HER2- Metastatic Breast Cancer (MBC)
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p2-07-16
Abstract: Background: Treatment with endocrine therapy and CDK4/6 inhibitors is the first-line therapy for the management of HR+/HER2- mBC. ESR1 mutations represent a type of acquired resistance in up to 40% of patients after initial ET.… read more here.
Keywords: cancer; resistance; therapy; esr1 ... See more keywords